18th Apr 2016 07:00
18 April 2016
Motif Bio plc
("Motif Bio" or the "Company")
Notice of Results
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, will announce its financial results for the year ended 31 December 2015 on Wednesday 20 April 2016.
The Company will hold an analyst and investor conference call at 12:00 BST (07.00 EST) on Wednesday 20 April 2016. The conference call will be hosted by Motif Bio's Chairman Richard Morgan and CEO Graham Lumsden and will cover the Company's full year results which will have been announced earlier in the day. No additional operational or financial information will be disclosed.
The conference call will commence at 12.00 BST (07.00 EST) and is expected to close by 13:00 BST (08.00 EST).
To join the call, participants should dial:
• United Kingdom; 0800 368 0649
• United Kingdom (Local); 020 3059 8125
• All Other Locations; +44 20 3059 8125
On joining the call, participants must quote the password 'sciences' to the operator, in order to gain access to the conference.
For further information please contact:
Motif Bio plc Graham Lumsden (Chief Executive Officer)
|
|
Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Dan Bate Dominic Wilson
| +44 (0)20 3829 5000 |
Northland Capital Partners Limited (BROKER) Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking) | +44 (0)203 861 6625 |
Walbrook PR Ltd. (FINANCIAL PR & IR) Paul McManus Mike Wort | +44 (0) 20 7933 8780 or [email protected] Mob: +44 (0)7980 541 893 Mob: +44 (0)7900 608 002 |
MC Services AG (EUROPEAN IR) Raimund Gabriel
|
+49 (0)89 210 2280
|
About Motif Bio (www.motifbio.com)
Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.
Related Shares:
MTFB.L